It is alarming that globally, only 2.2%(6.6 million) of patients with chronic hepatitis B (CHB)
received treatment in 2019. One contributing factor to this low treatment rate is the …

(1) Background: Hepatocellular carcinoma (HCC) is one of the deadliest cancers globally,
killing over 700,000 people each year. Despite the rising incidence and mortality rates of …

Hepatoma, or primary hepatocellular carcinoma(HCC), occurs infrequently in the United
States, with fewer than 10,000 new patients annually accounting for less than 2% of all …

Hepatocellular carcinoma (HCC) is the fifth most common form of human cancer worldwide
and the third most common cause of cancer-related deaths. The strategies of various …

Background Worldwide, hepatocellular carcinoma (HCC) is a universal problem and its
epidemiological data showed variation from place to place. Hepatocellular carcinoma (HCC) …

Hepatocellular carcinoma (HCC) is typically diagnosed late in the course of patients with
chronic liver disease and cirrhosis. Hepatic reserve of the patient, as indicated by the …

Purpose To evaluate the characteristics and response to therapy for HCC in sub-Saharan
Africa. Patients and methods We retrospectively evaluated demographic, clinical and …

Hepatocellular carcinoma (HCC) is one of the most common causes of cancer‐related
mortality worldwide. In the last few decades, there has been a marked increase in …

The Middle East comprises a heterogeneous collection of mainly Muslim and Arab
countries. In some discussions, nearby countries have also been included, such as those …

e16339 Background: Hepatocellular carcinoma (HCC) is increasing worldwide with limited
treatment options, a poor prognosis, and survival rates of less than 5 years. In Sub-Saharan …